Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification

Abstract A 72‐year‐old man with metastatic hepatocellular carcinoma previously received first‐line systemic therapy with atezolizumab plus bevacizumab. His disease was judged to be progressing 5 months after treatment initiation. Comprehensive genomic profiling revealed cytoplasmic mesenchymal–epithelial transition factor amplification. On the basis of an expert panel's recommendation, he received cabozantinib as second‐line therapy. The tumors shrank markedly and continued to shrink 6 months after treatment. Comprehensive genomic profiling could provide useful information for selecting effective second‐line treatments for patients with hepatocellular carcinoma after first‐line immunotherapy.